Last reviewed · How we verify
Muscle relaxant therapy
Muscle relaxant therapy reduces muscle tone and tension by depressing neuromuscular transmission or central nervous system activity.
Muscle relaxant therapy reduces muscle tone and tension by depressing neuromuscular transmission or central nervous system activity. Used for Muscle spasms and spasticity, Musculoskeletal pain and stiffness.
At a glance
| Generic name | Muscle relaxant therapy |
|---|---|
| Also known as | Vecuronium Bromide, Succinylcholine |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | Muscle relaxant |
| Modality | Small molecule |
| Therapeutic area | Musculoskeletal/Pain Management |
| Phase | FDA-approved |
Mechanism of action
Muscle relaxants work through various mechanisms including blocking neuromuscular junction transmission, enhancing inhibitory neurotransmitter activity in the spinal cord, or reducing motor neuron excitability. This results in decreased muscle contractility and relief of muscle spasticity or tension associated with musculoskeletal conditions.
Approved indications
- Muscle spasticity
- Musculoskeletal pain and tension
- Post-operative muscle relaxation
Common side effects
- Drowsiness
- Dizziness
- Weakness
- Headache
Key clinical trials
- Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia (NA)
- Comparing Ultrasound-Guided Transgluteal Nerve Block to Standard Care (NA)
- Long-term Potentiation Disruption Underlying Cognitive Impairment in ECT (EARLY_PHASE1)
- Different Transcutaneous Electrical Nerve Stimulation Modes in Pudendal Neuralgia Post-prostatectomy (NA)
- Orthosis to Improve Trunk Control in Infants Age 6-18 Months
- The Effect of Chiropractic Care on Opioid Use for Chronic Spinal Pain: A Feasibility Study (NA)
- Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19 (NA)
- General Anesthesia vs Local Anesthesia for Endovascular Treatment in Patients With Unruptured Intracranial Aneurysm Using Flow Diverter (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |